The findings, published Oct. 7 in Immunity, could lead to new treatments targeting IL-1β to better manage inflammation in patients who don't respond well to existing therapies.
Lupus is considered an 'interferonopathy' because almost all patients show elevated interferon activity in their blood and tissues, surprising us to find co-activation with IL-1β pathways.
Collection
[
|
...
]